Welcome back to another edition of Endpoints Weekly. Thanks to everyone who came out to our AI Day event this week in New ...
Eli Lilly's neuroscience president Carole Ho expressed interest in ibogaine R&D at NYC's Psychedelic Healthcare Forum, ...
Research shows 952K+ US clinicians made 271M queries to AI tool OpenEvidence from Jan 2024–June 2026. But there are concerns ...
Novartis terminated a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” according to a ...
More former Genentech leaders are finding a new home. Lélia Delamarre posted on LinkedIn that she’s leading R&D at ARCH-backed cancer biotech Medici Therapeutics, one of this year’s Endpoints 11 ...
China's Commerce Ministry proposes restricting export of cell/gene therapy, siRNA, and pathogen tech, while preserving drug ...
Mirum's Livmarli, First Tracks' ANB033, and Tortugas' obuprazine showed positive Phase 3, 1b, and 2b trial results in liver ...
NorthStar/Quarkmed, Lonza/Qurient CDK7 deal, Triastek/J&J 3D printing pact, Scinai's $5.1M deal & HydRegen's $8M Series A led ...
OMass has raised one of the largest private financings for a UK biotech in recent years as it seeks to follow in the ...
Paul Stoffels’ new Armed Cell Therapeutics buys Lakefront’s (ex-Galapagos) preclinical CAR-T work for $9M upfront, $230M in ...
Gilead pays Vir Biotechnology $65M upfront plus $25M investment for 3 T cell engager solid tumor therapies. Deal includes ...
Brent Saunders exits as Bausch + Lomb CEO by mutual agreement, replaced interim by Thomas Appio. Shares down 3%. Company to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results